Navigation Links
Everist Genomics Announces Worldwide Availability of OncoDefender™-CRC
Date:3/28/2011

ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ -- Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.  The OncoDefender-CRC test examines expression levels of a panel of genes extracted from formalin-fixed paraffin-embedded cancer tissue taken at the time of surgery, and uses a proprietary computer-generated decision rule to identify patients who are at risk of recurrence.  Patients identified by OncoDefender-CRC at high-risk of cancer recurrence may benefit from adjuvant therapy or other more aggressive treatment options, as reported at the 2011 American Society of Clinical Oncology (ASCO) meeting. (1)

(Logo: https://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

"We are pleased to deliver a new molecular prognostic test capable of assessing recurrence risk in early stage colorectal cancer patients, including the neglected stage I subset, where the lack of positive predictive prognostics presents a significant unmet need," said Prasad Sunkara, Ph.D., Chief Executive Officer of Everist Genomics.  OncoDefender-CRC was developed through extensive clinical research and assay validation studies involving over 500 patients from around the world.  "OncoDefender-CRC will help physicians make patient management decisions that promptly and reliably direct the most effective treatment to those individual Stage I/II colon cancer and Stage I rectal cancer patients at high risk for tumor recurrence, while minimizing the exposure of low-risk patients to unnecessary, costly, and potentially toxic chemotherapy and/or radiotherapy."

Traditional standards for assessing a patient's risk of cancer recurrence have depended solely on the cancer's a
'/>"/>

SOURCE Everist Genomics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genetics Squared Changes Name To Everist Genomics
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
6. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
10. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
11. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... to a survey by KLAS, an independent research firm, ... the number one ranking in the medical and/or radiology ... report. The survey of 247 customers of various vendors ... take a commanding lead over their competitors." MOSAIQ scored ... they would buy again and 96 percent confirmed that ...
(Date:10/25/2014)... Oct. 24, 2014 Research and Markets ... Market Current Trends, Opportunities - Global Forecast to 2019" ... this report, the global dental equipment market is categorized ... systems and equipment market is expected to register the ... the forecast period (2014 to 2019). This high growth ...
(Date:10/25/2014)... , Oct. 24, 2014 Advanced Photonix ® ... (ending September 26, 2014) financial results on Monday, November 10, ... released after the close of the market and the Company ... results at 4:30 p.m. EDT on the same day. ... (CEO and Director), Rob Risser (COO and ...
Breaking Medicine Technology:Elekta's MOSAIQ oncology information system ranks number one in KLAS Oncology 2014 report 2Elekta's MOSAIQ oncology information system ranks number one in KLAS Oncology 2014 report 3Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 2Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 3Advanced Photonix to Webcast Fiscal 2015 Second Quarter Earnings 2
(Date:10/25/2014)... 26, 2014 LunaDress is excited to ... wedding dresses today. According to the company’s CEO, ... especially those dwelling in the UK. The company’s new ... They are all unpretentious and elegant. , These new ... inputs from top dress experts. LunaDress strives to provide ...
(Date:10/25/2014)... (PRWEB) October 26, 2014 Recently, ... best Joomla hosting suppliers of 2014. . According ... among the most excellent suppliers in the world. ... for webmasters to make money from hosting. The ... resources to host the others’ websites under a ...
(Date:10/25/2014)... Top 10 Best SEO Hosting is ... The site has recently compared many hosting companies and ... among the most reliable Linux web hosting companies in ... Best SEO Hosting says, “The hosting suppliers we recommend ... outperform their competitors on hosting features, uptime and server ...
(Date:10/25/2014)... 26, 2014 The past five ... Sugar Cane Growing industry in Australia . ... by extreme weather patterns, volatile commodity prices and ... industry analyst Brooke Tonkin, “Over the period, flooding ... of Australia's sugar cane crop.” Consequently, industry revenue ...
(Date:10/25/2014)... Diego, CA (PRWEB) October 25, 2014 ... synthetic biology, today announced Dr. Xun ... of all Research & Development. , Triton has developed ... high value algae-based proteins. According to Dr. Wang, the ... over traditional expression systems. He says, “Algae are unique ...
Breaking Medicine News(10 mins):Health News:LunaDress Now Release Its Designer Inspired Fashion Wedding Dresses For Customers Dwelling In The UK 2Health News:Top10BestSEOHosting.com: GoDaddy, Bluehost And Hostgator Are Among The Most Excellent Suppliers In The World 2Health News:Top 10 Best SEO Hosting Announces That GreenGeeks.com And HostMonster Are Among The Most Reliable Linux Web Hosting Companies In 2014 2Health News:Sugar Cane Growing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Cane Growing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3
... Cosmecueticals, beauty aids that reportedly work like prescription drugs, ... study recently published in the Journal of Cosmetic Dermatology ... provide a visibly noticeable improvement in maturing skin. , ... the lack of skin surface regularity, formation of wrinkles, ...
... 28 Versus,Technology, Inc. ("Versus" or the "Company") ... October 31, 2007, compared to,revenues of $2,177,000 for ... year,ended October 31, 2007, were $5,566,000 compared to ... vary significantly depending on,the timing and delivery of ...
... MB Software,Corporation (OTC Bulletin Board: MBSB) announced ... Equity Partners to issue 490.196 shares of its,Series ... cancellation of,approximately $1,500,000 in debt. The debt was ... affiliates. The preferred stock will,automatically convert into an ...
... gadolinium-containing contrast injections in adults and pediatric patients (those ... to a recent study conducted by researchers at the ... these reactions do occur, most of them are mild, ... study. , Over the past few years, the ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... 28 Lincare Holdings,Inc. (Nasdaq: LNCR ) today ... and Exchange Commission (the "SEC") a resale shelf registration,statement ... pursuant to the terms,of a registration rights agreement Lincare ... sale of its $275 million principal amount of,convertible senior ...
Cached Medicine News:Health News:Versus Technology Announces Fourth Quarter Results 2Health News:Versus Technology Announces Fourth Quarter Results 3Health News:Versus Technology Announces Fourth Quarter Results 4Health News:Versus Technology Announces Fourth Quarter Results 5Health News:Versus Technology Announces Fourth Quarter Results 6Health News:Versus Technology Announces Fourth Quarter Results 7Health News:MB Software Corporation Reaches Agreement with Keystone Equity Partners 2Health News:Allergic reactions to gadolinium-based contrast agents are rare, study finds 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement 2
... including the Ceralas D and SmilePro 980 ... medical, dental, and veterinary environments.,With unsurpassed, optimal ... nm laser series allow controlled tissue ablation ... surgical procedures. Unlike other medical lasers, biolitecs ...
... Assay is a second generation nucleic acid ... in vitro qualitative detection and differentiation of ... uses a family of Gen-Probe's proven technologies ... and Dual Kinetic Assay (DKA). This is ...
... The InTray™ GC is a ... detection of both Neisseria gonorrhoeae and ... a long shelf life and is ... system. Simply inoculate, incubate and ...
... designed for patients with a spherical hyperopia between ... who would benefit from a spherical treatment of ... a myopic endpoint of between -1.00 D and ... improve near vision. CK is unique in that ...
Medicine Products: